Fundamental studies comparing nanobubbles and microbubbles as vascular disrupting agents: Elucidating on the mechanism of action using photoacoustic imaging (Conference Presentation)

2020 ◽  
Author(s):  
Eno Hysi ◽  
Muhannad N. Fadhel ◽  
Anoja Giles ◽  
Yanjie Wang ◽  
Joseph A. Sebastian ◽  
...  
Keyword(s):  
Mechanism Of Action ◽  
Photoacoustic Imaging ◽  
Vascular Disrupting Agents ◽  
Vascular Disrupting

Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non‐Small Cell Lung Cancer

2009 ◽  
Vol 14 (6) ◽  
pp. 612-620 ◽  
Author(s):  
Cesare Gridelli ◽  
Antonio Rossi ◽  
Paolo Maione ◽  
Emanuela Rossi ◽  
Vincenzo Castaldo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mechanism Of Action ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Vascular Disrupting Agents ◽  
Vascular Disrupting

scholarly journals Synthesis and Cytotoxic Activity of Several Novel N-Alkyl-Plinabulin Derivatives With Aryl Group Moieties

2021 ◽  
Vol 16 (4) ◽  
pp. 1934578X2110100
Author(s):  
Pham The Chinh ◽  
Pham Thi Tham ◽  
Duong Huong Quynh ◽  
Nguyen Van Tuyen ◽  
Dinh Thuy Van ◽  
...  
Keyword(s):  
Cytotoxic Activity ◽  
Cancer Cells ◽  
Cell Lines ◽  
Cancer Cell ◽  
Aldol Condensation ◽  
One Pot ◽  
Aryl Group ◽  
Vascular Disrupting Agents ◽  
Benzaldehyde Derivatives ◽  
Vascular Disrupting

Seven novel N-alkyl-plinabulin derivatives with aryl groups moieties (nitroquinoline, 1,4-dihydroquinoline, 4-methoxybenzene, and 4-chlorobenzene) have been synthesized via aldol condensation and alkylation in one-pot, and tested for their cytotoxicity against 4 cancer cell lines (KB, HepG2, Lu, and MCF7). Compounds ( Z)−3-((6,8-dimethyl-4-oxo-1,4-dihydroquinolin-2-yl)methylene)−6-(( Z)−4-methoxybenzylidene)−1-(prop-2-yn-1-yl)piperazine-2,5-dione (5a), ( Z)−6-(( Z)−4-methoxybenzylidene)−1-(prop-2-yn-1-yl)−3-((1,6,8-trimethyl-4-oxo-1,4-dihydroquinolin-2-yl)methylene)piperazine-2,5-dione (5b), and ( Z)−3-(( Z)−4-chlorobenzylidene)−1,4-dimethyl-6-((8-methyl-4-nitroquinolin-2-yl)methylene)piperazine-2,5-dione (8) showed strong cytotoxicity against 3 of the cancer cells lines (KB, HepG2 and Lu) with IC50 values ranging from 3.04 to 10.62 µM. The quinoline-derived compounds had higher cytotoxic activity than the benzaldehyde derivatives. The successful synthesis of these derivatives offers useful information for the development of more potent vascular disrupting agents based on plinabulin.

Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic

2011 ◽  
Vol 12 (14) ◽  
pp. 2009-2015 ◽  
Author(s):  
Matthew A. Spear ◽  
Patricia LoRusso ◽  
Alain Mita ◽  
Monica Mita
Keyword(s):  
Vascular Disrupting Agents ◽  
Vascular Disrupting

scholarly journals Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy

ChemMedChem ◽  
2018 ◽  
Vol 13 (24) ◽  
pp. 2618-2626 ◽  
Author(s):  
Andrew W. Brown ◽  
Toby Holmes ◽  
Matthew Fisher ◽  
Gillian M. Tozer ◽  
Joseph P. A. Harrity ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Vascular Disrupting Agents ◽  
Vascular Disrupting

scholarly journals Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation

Diagnostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 78 ◽  
Author(s):  
Yewei Liu ◽  
Shuncong Wang ◽  
Xiaohui Zhao ◽  
Yuanbo Feng ◽  
Guy Bormans ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Liver Cancer ◽  
Human Liver ◽  
Cellular Differentiation ◽  
Liver Tumors ◽  
Pancreatic Tumors ◽  
Imaging Biomarkers ◽  
Vascular Disrupting Agents ◽  
Liver Cancers ◽  
Vascular Disrupting

Vascular disrupting agents (VDAs) have entered clinical trials for over 15 years. As the leading VDA, combretastatin A4 phosphate (CA4P) has been evaluated in combination with chemotherapy and molecular targeting agents among patients with ovarian cancer, lung cancer and thyroid cancer, but still remains rarely explored in human liver cancers. To overcome tumor residues and regrowth after CA4P monotherapy, a novel dual targeting pan-anticancer theragnostic strategy, i.e., OncoCiDia, has been developed and shown promise previously in secondary liver tumor models. Animal model of primary liver cancer is time consuming to induce, but of value for more closely mimicking human liver cancers in terms of tumor angiogenesis, histopathological heterogeneity, cellular differentiation, tumor components, cancer progression and therapeutic response. Being increasingly adopted in VDA researches, multiparametric magnetic resonance imaging (MRI) provides imaging biomarkers to reflect in vivo tumor responses to drugs. In this article as a chapter of a doctoral thesis, we overview the construction and clinical relevance of primary and secondary liver cancer models in rodents. Target selection for CA4P therapy assisted by enhanced MRI using hepatobiliary contrast agents (CAs), and therapeutic efficacy evaluated by using MRI with a non-specific contrast agent, dynamic contrast enhanced (DCE) imaging, diffusion weighted imaging (DWI) are also described. We then summarize diverse responses among primary hepatocellular carcinomas (HCCs), secondary liver and pancreatic tumors to CA4P, which appeared to be related to tumor size, vascularity, and cellular differentiation. In general, imaging-histopathology correlation studies allow to conclude that CA4P tends to be more effective in secondary liver tumors and in more differentiated HCCs, but less effective in less differentiated HCCs and implanted pancreatic tumor. Notably, cirrhotic liver may be responsive to CA4P as well. All these could be instructive for future clinical trials of VDAs.

Sign in / Sign up

Export Citation Format

Share Document